Sample size requirements to estimate key design parameters from external pilot randomised controlled trials: a simulation study

External pilot or feasibility studies can be used to estimate key unknown parameters to inform the design of the definitive randomised controlled trial (RCT). However, there is little consensus on how large pilot studies need to be, and some suggest inflating estimates to adjust for the lack of prec...

Full description

Saved in:
Bibliographic Details
Published inTrials Vol. 15; no. 1; p. 264
Main Authors Teare, M Dawn, Dimairo, Munyaradzi, Shephard, Neil, Hayman, Alex, Whitehead, Amy, Walters, Stephen J
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 03.07.2014
BioMed Central
Subjects
Online AccessGet full text

Cover

Loading…
Abstract External pilot or feasibility studies can be used to estimate key unknown parameters to inform the design of the definitive randomised controlled trial (RCT). However, there is little consensus on how large pilot studies need to be, and some suggest inflating estimates to adjust for the lack of precision when planning the definitive RCT. We use a simulation approach to illustrate the sampling distribution of the standard deviation for continuous outcomes and the event rate for binary outcomes. We present the impact of increasing the pilot sample size on the precision and bias of these estimates, and predicted power under three realistic scenarios. We also illustrate the consequences of using a confidence interval argument to inflate estimates so the required power is achieved with a pre-specified level of confidence. We limit our attention to external pilot and feasibility studies prior to a two-parallel-balanced-group superiority RCT. For normally distributed outcomes, the relative gain in precision of the pooled standard deviation (SDp) is less than 10% (for each five subjects added per group) once the total sample size is 70. For true proportions between 0.1 and 0.5, we find the gain in precision for each five subjects added to the pilot sample is less than 5% once the sample size is 60. Adjusting the required sample sizes for the imprecision in the pilot study estimates can result in excessively large definitive RCTs and also requires a pilot sample size of 60 to 90 for the true effect sizes considered here. We recommend that an external pilot study has at least 70 measured subjects (35 per group) when estimating the SDp for a continuous outcome. If the event rate in an intervention group needs to be estimated by the pilot then a total of 60 to 100 subjects is required. Hence if the primary outcome is binary a total of at least 120 subjects (60 in each group) may be required in the pilot trial. It is very much more efficient to use a larger pilot study, than to guard against the lack of precision by using inflated estimates.
AbstractList External pilot or feasibility studies can be used to estimate key unknown parameters to inform the design of the definitive randomised controlled trial (RCT). However, there is little consensus on how large pilot studies need to be, and some suggest inflating estimates to adjust for the lack of precision when planning the definitive RCT. We use a simulation approach to illustrate the sampling distribution of the standard deviation for continuous outcomes and the event rate for binary outcomes. We present the impact of increasing the pilot sample size on the precision and bias of these estimates, and predicted power under three realistic scenarios. We also illustrate the consequences of using a confidence interval argument to inflate estimates so the required power is achieved with a pre-specified level of confidence. We limit our attention to external pilot and feasibility studies prior to a two-parallel-balanced-group superiority RCT. For normally distributed outcomes, the relative gain in precision of the pooled standard deviation (SDp) is less than 10% (for each five subjects added per group) once the total sample size is 70. For true proportions between 0.1 and 0.5, we find the gain in precision for each five subjects added to the pilot sample is less than 5% once the sample size is 60. Adjusting the required sample sizes for the imprecision in the pilot study estimates can result in excessively large definitive RCTs and also requires a pilot sample size of 60 to 90 for the true effect sizes considered here. We recommend that an external pilot study has at least 70 measured subjects (35 per group) when estimating the SDp for a continuous outcome. If the event rate in an intervention group needs to be estimated by the pilot then a total of 60 to 100 subjects is required. Hence if the primary outcome is binary a total of at least 120 subjects (60 in each group) may be required in the pilot trial. It is very much more efficient to use a larger pilot study, than to guard against the lack of precision by using inflated estimates.
External pilot or feasibility studies can be used to estimate key unknown parameters to inform the design of the definitive randomised controlled trial (RCT). However, there is little consensus on how large pilot studies need to be, and some suggest inflating estimates to adjust for the lack of precision when planning the definitive RCT. We use a simulation approach to illustrate the sampling distribution of the standard deviation for continuous outcomes and the event rate for binary outcomes. We present the impact of increasing the pilot sample size on the precision and bias of these estimates, and predicted power under three realistic scenarios. We also illustrate the consequences of using a confidence interval argument to inflate estimates so the required power is achieved with a pre-specified level of confidence. We limit our attention to external pilot and feasibility studies prior to a two-parallel-balanced-group superiority RCT. For normally distributed outcomes, the relative gain in precision of the pooled standard deviation (SD.sub.p) is less than 10% (for each five subjects added per group) once the total sample size is 70. For true proportions between 0.1 and 0.5, we find the gain in precision for each five subjects added to the pilot sample is less than 5% once the sample size is 60. Adjusting the required sample sizes for the imprecision in the pilot study estimates can result in excessively large definitive RCTs and also requires a pilot sample size of 60 to 90 for the true effect sizes considered here. We recommend that an external pilot study has at least 70 measured subjects (35 per group) when estimating the SD.sub.p for a continuous outcome. If the event rate in an intervention group needs to be estimated by the pilot then a total of 60 to 100 subjects is required. Hence if the primary outcome is binary a total of at least 120 subjects (60 in each group) may be required in the pilot trial. It is very much more efficient to use a larger pilot study, than to guard against the lack of precision by using inflated estimates.
Background External pilot or feasibility studies can be used to estimate key unknown parameters to inform the design of the definitive randomised controlled trial (RCT). However, there is little consensus on how large pilot studies need to be, and some suggest inflating estimates to adjust for the lack of precision when planning the definitive RCT. Methods We use a simulation approach to illustrate the sampling distribution of the standard deviation for continuous outcomes and the event rate for binary outcomes. We present the impact of increasing the pilot sample size on the precision and bias of these estimates, and predicted power under three realistic scenarios. We also illustrate the consequences of using a confidence interval argument to inflate estimates so the required power is achieved with a pre-specified level of confidence. We limit our attention to external pilot and feasibility studies prior to a two-parallel-balanced-group superiority RCT. Results For normally distributed outcomes, the relative gain in precision of the pooled standard deviation (SD.sub.p) is less than 10% (for each five subjects added per group) once the total sample size is 70. For true proportions between 0.1 and 0.5, we find the gain in precision for each five subjects added to the pilot sample is less than 5% once the sample size is 60. Adjusting the required sample sizes for the imprecision in the pilot study estimates can result in excessively large definitive RCTs and also requires a pilot sample size of 60 to 90 for the true effect sizes considered here. Conclusions We recommend that an external pilot study has at least 70 measured subjects (35 per group) when estimating the SD.sub.p for a continuous outcome. If the event rate in an intervention group needs to be estimated by the pilot then a total of 60 to 100 subjects is required. Hence if the primary outcome is binary a total of at least 120 subjects (60 in each group) may be required in the pilot trial. It is very much more efficient to use a larger pilot study, than to guard against the lack of precision by using inflated estimates. Keywords: sample size, feasibility studies, pilot studies, binary outcomes, continuous outcomes, RCTs
BACKGROUND: External pilot or feasibility studies can be used to estimate key unknown parameters to inform the design of the definitive randomised controlled trial (RCT). However, there is little consensus on how large pilot studies need to be, and some suggest inflating estimates to adjust for the lack of precision when planning the definitive RCT. METHODS: We use a simulation approach to illustrate the sampling distribution of the standard deviation for continuous outcomes and the event rate for binary outcomes. We present the impact of increasing the pilot sample size on the precision and bias of these estimates, and predicted power under three realistic scenarios. We also illustrate the consequences of using a confidence interval argument to inflate estimates so the required power is achieved with a pre-specified level of confidence. We limit our attention to external pilot and feasibility studies prior to a two-parallel-balanced-group superiority RCT. RESULTS: For normally distributed outcomes, the relative gain in precision of the pooled standard deviation (SDp) is less than 10% (for each five subjects added per group) once the total sample size is 70. For true proportions between 0.1 and 0.5, we find the gain in precision for each five subjects added to the pilot sample is less than 5% once the sample size is 60. Adjusting the required sample sizes for the imprecision in the pilot study estimates can result in excessively large definitive RCTs and also requires a pilot sample size of 60 to 90 for the true effect sizes considered here. CONCLUSIONS: We recommend that an external pilot study has at least 70 measured subjects (35 per group) when estimating the SDp for a continuous outcome. If the event rate in an intervention group needs to be estimated by the pilot then a total of 60 to 100 subjects is required. Hence if the primary outcome is binary a total of at least 120 subjects (60 in each group) may be required in the pilot trial. It is very much more efficient to use a larger pilot study, than to guard against the lack of precision by using inflated estimates.
External pilot or feasibility studies can be used to estimate key unknown parameters to inform the design of the definitive randomised controlled trial (RCT). However, there is little consensus on how large pilot studies need to be, and some suggest inflating estimates to adjust for the lack of precision when planning the definitive RCT.BACKGROUNDExternal pilot or feasibility studies can be used to estimate key unknown parameters to inform the design of the definitive randomised controlled trial (RCT). However, there is little consensus on how large pilot studies need to be, and some suggest inflating estimates to adjust for the lack of precision when planning the definitive RCT.We use a simulation approach to illustrate the sampling distribution of the standard deviation for continuous outcomes and the event rate for binary outcomes. We present the impact of increasing the pilot sample size on the precision and bias of these estimates, and predicted power under three realistic scenarios. We also illustrate the consequences of using a confidence interval argument to inflate estimates so the required power is achieved with a pre-specified level of confidence. We limit our attention to external pilot and feasibility studies prior to a two-parallel-balanced-group superiority RCT.METHODSWe use a simulation approach to illustrate the sampling distribution of the standard deviation for continuous outcomes and the event rate for binary outcomes. We present the impact of increasing the pilot sample size on the precision and bias of these estimates, and predicted power under three realistic scenarios. We also illustrate the consequences of using a confidence interval argument to inflate estimates so the required power is achieved with a pre-specified level of confidence. We limit our attention to external pilot and feasibility studies prior to a two-parallel-balanced-group superiority RCT.For normally distributed outcomes, the relative gain in precision of the pooled standard deviation (SDp) is less than 10% (for each five subjects added per group) once the total sample size is 70. For true proportions between 0.1 and 0.5, we find the gain in precision for each five subjects added to the pilot sample is less than 5% once the sample size is 60. Adjusting the required sample sizes for the imprecision in the pilot study estimates can result in excessively large definitive RCTs and also requires a pilot sample size of 60 to 90 for the true effect sizes considered here.RESULTSFor normally distributed outcomes, the relative gain in precision of the pooled standard deviation (SDp) is less than 10% (for each five subjects added per group) once the total sample size is 70. For true proportions between 0.1 and 0.5, we find the gain in precision for each five subjects added to the pilot sample is less than 5% once the sample size is 60. Adjusting the required sample sizes for the imprecision in the pilot study estimates can result in excessively large definitive RCTs and also requires a pilot sample size of 60 to 90 for the true effect sizes considered here.We recommend that an external pilot study has at least 70 measured subjects (35 per group) when estimating the SDp for a continuous outcome. If the event rate in an intervention group needs to be estimated by the pilot then a total of 60 to 100 subjects is required. Hence if the primary outcome is binary a total of at least 120 subjects (60 in each group) may be required in the pilot trial. It is very much more efficient to use a larger pilot study, than to guard against the lack of precision by using inflated estimates.CONCLUSIONSWe recommend that an external pilot study has at least 70 measured subjects (35 per group) when estimating the SDp for a continuous outcome. If the event rate in an intervention group needs to be estimated by the pilot then a total of 60 to 100 subjects is required. Hence if the primary outcome is binary a total of at least 120 subjects (60 in each group) may be required in the pilot trial. It is very much more efficient to use a larger pilot study, than to guard against the lack of precision by using inflated estimates.
ArticleNumber 264
Audience Academic
Author Walters, Stephen J
Hayman, Alex
Whitehead, Amy
Dimairo, Munyaradzi
Shephard, Neil
Teare, M Dawn
AuthorAffiliation 1 Design, Trials and Statistics Group, School of Health and Related Research, University of Sheffield, Regent Court, 30 Regent Street, S1 4DA Sheffield, UK
AuthorAffiliation_xml – name: 1 Design, Trials and Statistics Group, School of Health and Related Research, University of Sheffield, Regent Court, 30 Regent Street, S1 4DA Sheffield, UK
Author_xml – sequence: 1
  givenname: M Dawn
  surname: Teare
  fullname: Teare, M Dawn
– sequence: 2
  givenname: Munyaradzi
  surname: Dimairo
  fullname: Dimairo, Munyaradzi
– sequence: 3
  givenname: Neil
  surname: Shephard
  fullname: Shephard, Neil
– sequence: 4
  givenname: Alex
  surname: Hayman
  fullname: Hayman, Alex
– sequence: 5
  givenname: Amy
  surname: Whitehead
  fullname: Whitehead, Amy
– sequence: 6
  givenname: Stephen J
  surname: Walters
  fullname: Walters, Stephen J
BackLink https://www.ncbi.nlm.nih.gov/pubmed/24993581$$D View this record in MEDLINE/PubMed
BookMark eNp1kstv1DAQxiNURB9w54QsceGSEj_iOByQqlV5SJU4AGfLSSaLwbG3toNYLv3XmbBl1UWtYikjz28-e-bzaXHkg4eieE6rc0qVfE0bUZeS0brExaR4VJzst47uxMfFaUrfq0rwlosnxTETbctrRU-Km89m2jggyf4GEuF6thEm8DmRHAikbCeTgfyALRkg2bUnGxPNBBliImMME4FfGHvjyMa6kEk0fgiTTTCQPvgcg3MY5miNS2-IwXOm2Zlsgycpz8P2afF4xBQ8u_2fFV_fXX5ZfSivPr3_uLq4Krua8VyOxhgGwtBWNs0g65YKhnGnmGKGceBVr-TQAW1aNcqOC941nEtQ4wBjqxQ_K97udDdzN8HQY4vROL2J2GDc6mCsPsx4-02vw08tGGtYuwisdgKdDQ8IHGb6MOnFAL0YoHGhP6jy6vYaMVzPOF-Ns-rBOeMhzAkxoaSoFK8RfblD18aBtn4MKNsvuL6oRSVVLZqFOr-Hwm-AyaIDMFrcPyh4cXcQ-wb-PQkEqh3Qx5BShHGP0Eovr-6-ruR_Jb3Nf03Gy1j3cOEfcYjdqQ
CitedBy_id crossref_primary_10_1093_rheumatology_keaa890
crossref_primary_10_3389_fnbeh_2019_00115
crossref_primary_10_1016_j_diabres_2020_108541
crossref_primary_10_1016_j_apmr_2018_06_032
crossref_primary_10_3390_ijerph17186902
crossref_primary_10_1186_s40814_023_01304_3
crossref_primary_10_3390_jcm10143087
crossref_primary_10_1016_j_xfre_2022_11_005
crossref_primary_10_1186_s12877_022_03452_2
crossref_primary_10_54005_geneltip_1298917
crossref_primary_10_1186_s40814_021_00798_z
crossref_primary_10_3389_fpsyt_2023_1272396
crossref_primary_10_3310_hta23600
crossref_primary_10_3399_bjgp19X704573
crossref_primary_10_1016_j_ejon_2022_102202
crossref_primary_10_1039_D4FO03414G
crossref_primary_10_1016_j_nhres_2024_10_002
crossref_primary_10_1002_ijgo_14790
crossref_primary_10_1186_s12889_017_4167_1
crossref_primary_10_1371_journal_pmed_1004459
crossref_primary_10_1136_ijgc_2018_000039
crossref_primary_10_2196_54081
crossref_primary_10_20344_amp_18876
crossref_primary_10_1002_JPER_17_0591
crossref_primary_10_1016_j_jth_2021_101140
crossref_primary_10_3310_KQYT5412
crossref_primary_10_1186_s13063_015_0730_1
crossref_primary_10_1136_openhrt_2018_000841
crossref_primary_10_1186_s13063_020_04428_6
crossref_primary_10_1302_2633_1462_211_BJO_2021_0136
crossref_primary_10_1002_ksa_12430
crossref_primary_10_1007_s00520_019_04931_w
crossref_primary_10_1136_bmjebm_2023_112358
crossref_primary_10_1136_bmjopen_2019_035905
crossref_primary_10_1186_s13063_016_1260_1
crossref_primary_10_1111_joor_13231
crossref_primary_10_34108_eujhs_1090840
crossref_primary_10_1080_10641955_2020_1869250
crossref_primary_10_1177_0269215517692129
crossref_primary_10_1186_s40814_021_00929_6
crossref_primary_10_1186_s13063_018_2767_4
crossref_primary_10_1016_j_bandc_2021_105811
crossref_primary_10_1016_j_cllc_2017_11_008
crossref_primary_10_1186_s40814_021_00796_1
crossref_primary_10_1016_j_cmi_2018_10_019
crossref_primary_10_1136_bmjopen_2022_064792
crossref_primary_10_1136_bmjopen_2020_048204
crossref_primary_10_1186_s13063_020_04810_4
crossref_primary_10_1089_tmj_2017_0166
crossref_primary_10_1001_jamapediatrics_2024_3997
crossref_primary_10_1177_20552076251326229
crossref_primary_10_1136_bmjopen_2022_065646
crossref_primary_10_1080_15502783_2022_2097018
crossref_primary_10_1097_WON_0000000000000894
crossref_primary_10_1136_bmjopen_2023_083235
crossref_primary_10_1111_codi_17194
crossref_primary_10_1186_s13034_024_00721_3
crossref_primary_10_1371_journal_pone_0317425
crossref_primary_10_1186_s12875_023_02221_3
crossref_primary_10_3310_nihropenres_13284_2
crossref_primary_10_1183_23120541_00168_2024
crossref_primary_10_1186_s40814_024_01585_2
crossref_primary_10_1186_s40814_021_00896_y
crossref_primary_10_3310_nihropenres_13284_1
crossref_primary_10_1186_s12889_019_6734_0
crossref_primary_10_26603_001c_68141
crossref_primary_10_1097_PEC_0000000000002133
crossref_primary_10_1177_17407745221123507
crossref_primary_10_1183_23120541_00955_2020
crossref_primary_10_1111_bcp_13691
crossref_primary_10_1136_bmjopen_2020_046313
crossref_primary_10_1371_journal_pone_0292326
crossref_primary_10_1016_j_bja_2021_11_010
crossref_primary_10_3390_jcm12134237
crossref_primary_10_3310_hta21740
crossref_primary_10_1186_s13063_017_1841_7
crossref_primary_10_1186_s40814_020_00622_0
crossref_primary_10_1007_s40520_020_01475_6
crossref_primary_10_1016_j_invent_2021_100369
crossref_primary_10_1186_s40814_017_0177_0
crossref_primary_10_2196_45276
crossref_primary_10_1080_03610918_2024_2316281
crossref_primary_10_1186_s40814_023_01416_w
crossref_primary_10_1016_j_physio_2019_06_007
crossref_primary_10_2196_46008
crossref_primary_10_1159_000514524
crossref_primary_10_1183_23120541_00257_2022
crossref_primary_10_2196_34032
crossref_primary_10_1016_j_yebeh_2020_107581
crossref_primary_10_1186_s40814_020_00634_w
crossref_primary_10_1016_j_nedt_2018_01_024
crossref_primary_10_15406_mojsm_2023_06_00138
crossref_primary_10_1136_bmjopen_2019_035915
crossref_primary_10_1186_s40814_019_0457_y
crossref_primary_10_1136_bmjopen_2019_034708
crossref_primary_10_2196_48799
crossref_primary_10_1007_s10865_023_00455_1
crossref_primary_10_1016_j_schres_2024_11_007
crossref_primary_10_1186_s12889_021_11870_x
crossref_primary_10_1016_j_jpainsymman_2018_02_019
crossref_primary_10_1136_bmjopen_2023_075651
crossref_primary_10_3310_nihropenres_13275_1
crossref_primary_10_1186_s40814_023_01439_3
crossref_primary_10_1016_j_jneb_2023_09_006
crossref_primary_10_3310_nihropenres_13275_2
crossref_primary_10_1136_bjsports_2023_107505
crossref_primary_10_1136_bmjopen_2020_038620
crossref_primary_10_1016_j_preghy_2019_09_018
crossref_primary_10_2196_36673
crossref_primary_10_1136_bmjopen_2016_015568
crossref_primary_10_1186_s40814_023_01272_8
crossref_primary_10_3389_fonc_2023_1110500
crossref_primary_10_1302_2633_1462_53_BJO_2023_0114
crossref_primary_10_1186_s40814_019_0456_z
crossref_primary_10_1080_13607863_2021_1985966
crossref_primary_10_1080_19317611_2023_2215766
crossref_primary_10_1186_s40814_024_01485_5
crossref_primary_10_1016_j_ctim_2024_103107
crossref_primary_10_1002_mus_28386
crossref_primary_10_1186_s40814_017_0189_9
crossref_primary_10_2139_ssrn_4116838
crossref_primary_10_2196_24106
crossref_primary_10_2196_40931
crossref_primary_10_1136_bmjopen_2024_094712
crossref_primary_10_1177_0260106018761282
crossref_primary_10_1080_13607863_2024_2449126
crossref_primary_10_1038_s41433_024_03273_0
crossref_primary_10_1192_bjo_2021_983
crossref_primary_10_3310_KNWT4781
crossref_primary_10_3390_jcm11051356
crossref_primary_10_21315_mjms2021_28_2_2
crossref_primary_10_3310_hta25070
crossref_primary_10_3390_vaccines12060608
crossref_primary_10_3390_biomedicines11051297
crossref_primary_10_2196_19232
crossref_primary_10_1186_s40814_021_00925_w
crossref_primary_10_1136_bmjopen_2023_073611
crossref_primary_10_1186_s40814_021_00901_4
crossref_primary_10_1016_j_ejogrb_2025_01_032
crossref_primary_10_1016_j_ijis_2024_07_002
crossref_primary_10_1186_s40814_023_01358_3
crossref_primary_10_1186_s13063_017_1792_z
crossref_primary_10_2196_19456
crossref_primary_10_1016_j_jcbs_2023_100720
crossref_primary_10_1017_S0033291724001144
crossref_primary_10_1186_s44247_023_00042_z
crossref_primary_10_1111_1471_0528_14552
crossref_primary_10_1177_0962280215588241
crossref_primary_10_1186_s40814_022_01186_x
crossref_primary_10_1055_a_2508_5757
crossref_primary_10_1016_j_jpainsymman_2024_03_015
crossref_primary_10_1159_000381957
crossref_primary_10_1177_0962280215588242
crossref_primary_10_1186_s40814_021_00770_x
crossref_primary_10_1007_s11096_019_00787_6
crossref_primary_10_1111_cns_13731
crossref_primary_10_3310_phr07200
crossref_primary_10_2196_resprot_6402
crossref_primary_10_1186_s40814_025_01608_6
crossref_primary_10_1016_j_invent_2021_100385
crossref_primary_10_1515_tnsci_2020_0003
crossref_primary_10_1007_s10103_020_03166_0
crossref_primary_10_1136_bmjopen_2019_030164
crossref_primary_10_1136_bmjopen_2020_044488
crossref_primary_10_1186_s40814_021_00803_5
crossref_primary_10_1186_s40814_020_00633_x
crossref_primary_10_2196_16089
crossref_primary_10_1177_15248399231221769
crossref_primary_10_3389_fmed_2021_639402
crossref_primary_10_1186_s12966_023_01443_z
crossref_primary_10_2196_resprot_7720
crossref_primary_10_3310_nihropenres_13507_1
crossref_primary_10_3310_nihropenres_13507_2
crossref_primary_10_1089_g4h_2021_0215
crossref_primary_10_2196_46951
crossref_primary_10_1136_bmjopen_2023_083635
crossref_primary_10_1136_bmjopen_2020_045741
crossref_primary_10_1136_bmjresp_2024_002698
crossref_primary_10_1371_journal_pone_0278418
crossref_primary_10_2196_58998
crossref_primary_10_1080_19466315_2020_1831951
crossref_primary_10_1007_s40609_019_00142_7
crossref_primary_10_1136_bmjopen_2021_050099
crossref_primary_10_1136_emermed_2024_213905
crossref_primary_10_1111_bjc_12209
crossref_primary_10_1136_gutjnl_2020_322756
crossref_primary_10_1186_s12874_024_02351_x
crossref_primary_10_1016_j_socscimed_2021_114191
crossref_primary_10_1136_bmjopen_2018_023123
crossref_primary_10_3310_nihropenres_13716_1
crossref_primary_10_1186_s40814_020_00709_8
crossref_primary_10_1016_j_bpsgos_2024_100308
crossref_primary_10_1002_sim_8941
crossref_primary_10_2196_47860
crossref_primary_10_3310_nihropenres_13716_2
crossref_primary_10_1186_s40814_016_0105_8
crossref_primary_10_1007_s10608_024_10516_7
crossref_primary_10_1177_20499361251314766
crossref_primary_10_3389_fneur_2021_675106
crossref_primary_10_1186_s40337_021_00426_4
crossref_primary_10_3310_hta25490
crossref_primary_10_1186_s40814_025_01606_8
crossref_primary_10_1017_S0033291721004797
crossref_primary_10_1519_SSC_0000000000000701
crossref_primary_10_1186_s11689_024_09584_3
crossref_primary_10_1016_j_ctim_2020_102494
crossref_primary_10_1016_S2215_0366_22_00103_1
crossref_primary_10_1200_OP_23_00016
crossref_primary_10_1136_bmjopen_2018_028721
crossref_primary_10_1016_j_physio_2015_12_001
crossref_primary_10_1186_s40814_018_0299_z
crossref_primary_10_1089_neu_2023_0465
crossref_primary_10_1186_s40814_020_00630_0
crossref_primary_10_1186_s13063_020_04673_9
crossref_primary_10_1093_jn_nxab087
crossref_primary_10_12688_hrbopenres_13981_1
crossref_primary_10_3389_fnagi_2020_00155
crossref_primary_10_1371_journal_pone_0238286
crossref_primary_10_1186_s13063_020_04553_2
crossref_primary_10_1136_bmjopen_2022_069593
crossref_primary_10_3390_ijerph20021185
crossref_primary_10_1093_abm_kaaf003
crossref_primary_10_1080_20008198_2019_1711349
crossref_primary_10_1055_s_0043_1778664
crossref_primary_10_1136_bmjopen_2024_084085
crossref_primary_10_1186_s40814_023_01354_7
crossref_primary_10_3310_nihropenres_13311_1
crossref_primary_10_3310_nihropenres_13311_2
crossref_primary_10_1161_CIRCULATIONAHA_119_045066
crossref_primary_10_1007_s43546_022_00321_3
crossref_primary_10_1093_pubmed_fdae017
crossref_primary_10_29392_001c_33812
crossref_primary_10_1016_j_arrct_2021_100151
crossref_primary_10_17267_2317_3378rec_2024_e5654
crossref_primary_10_1186_s12889_023_15347_x
crossref_primary_10_12688_f1000research_129158_1
crossref_primary_10_1016_j_ajem_2019_03_021
crossref_primary_10_1186_s40814_023_01256_8
crossref_primary_10_1186_s40814_024_01559_4
crossref_primary_10_1007_s12529_025_10352_3
crossref_primary_10_1136_bmjopen_2021_060280
crossref_primary_10_1186_s40814_020_00589_y
crossref_primary_10_1111_aogs_14760
crossref_primary_10_3389_fneur_2023_1302793
crossref_primary_10_1038_s41432_024_01098_0
crossref_primary_10_1016_j_jcbs_2024_100852
crossref_primary_10_1097_MBP_0000000000000644
crossref_primary_10_1186_s12877_023_04122_7
crossref_primary_10_1186_s40814_022_01129_6
crossref_primary_10_2147_DDDT_S490772
crossref_primary_10_1093_ntr_ntae056
crossref_primary_10_1136_bmjopen_2021_056091
crossref_primary_10_1186_s40814_018_0318_0
crossref_primary_10_1016_j_conctc_2022_101046
crossref_primary_10_1136_bmjresp_2018_000368
crossref_primary_10_1016_j_evalprogplan_2022_102070
crossref_primary_10_1136_bmjopen_2022_069443
crossref_primary_10_1371_journal_pone_0314829
crossref_primary_10_1136_bmjopen_2016_013906
crossref_primary_10_1001_jamanetworkopen_2022_21430
crossref_primary_10_1186_s13075_024_03291_z
crossref_primary_10_3390_economies13030066
crossref_primary_10_1177_20406223221080646
crossref_primary_10_3390_nu14173491
crossref_primary_10_1007_s10353_024_00828_z
crossref_primary_10_3310_hta25540
crossref_primary_10_2196_41590
crossref_primary_10_1186_s13063_018_2675_7
crossref_primary_10_1186_s13063_020_4181_y
crossref_primary_10_1136_bmjopen_2018_028428
crossref_primary_10_3310_phr08110
crossref_primary_10_1177_03128962241270860
crossref_primary_10_1093_sleep_zsad053
crossref_primary_10_1136_bmjopen_2023_078264
crossref_primary_10_1016_j_ijosm_2017_02_001
crossref_primary_10_1186_s40814_018_0328_y
crossref_primary_10_1002_gps_5154
crossref_primary_10_3390_healthcare7010027
crossref_primary_10_1016_j_conctc_2020_100572
crossref_primary_10_2196_34711
crossref_primary_10_1136_bmjopen_2022_065909
crossref_primary_10_1136_bmjopen_2023_082648
crossref_primary_10_1016_j_nicl_2023_103453
crossref_primary_10_1177_15347354251314514
crossref_primary_10_1371_journal_pone_0229483
crossref_primary_10_1136_bmjopen_2023_078273
crossref_primary_10_3390_ijerph19073778
crossref_primary_10_1080_10641955_2024_2439312
crossref_primary_10_3390_ijerph19063700
crossref_primary_10_1016_j_cct_2021_106323
crossref_primary_10_1002_sim_9091
crossref_primary_10_1186_s40814_018_0305_5
crossref_primary_10_1186_s40814_022_01139_4
crossref_primary_10_1038_s41533_022_00294_8
crossref_primary_10_2196_30327
crossref_primary_10_1186_s12909_024_06633_2
crossref_primary_10_1186_s40814_020_00661_7
crossref_primary_10_1186_s13063_018_2674_8
crossref_primary_10_3390_jcm10214984
crossref_primary_10_1080_17533015_2019_1703198
crossref_primary_10_1007_s43546_023_00481_w
crossref_primary_10_37382_jomts_v5i1_915
crossref_primary_10_1016_j_msksp_2023_102874
crossref_primary_10_1186_s40814_019_0417_6
crossref_primary_10_1192_bjo_2018_44
crossref_primary_10_1186_s40814_024_01448_w
crossref_primary_10_1093_rap_rkac086
crossref_primary_10_1017_S1368980023002471
crossref_primary_10_1186_s40814_021_00934_9
crossref_primary_10_1016_j_chstcc_2024_100109
crossref_primary_10_1136_bmjopen_2022_070590
crossref_primary_10_1016_j_invent_2024_100793
crossref_primary_10_2196_43645
crossref_primary_10_1515_jom_2020_0320
crossref_primary_10_1136_bmjopen_2022_070865
crossref_primary_10_1186_s40814_023_01286_2
crossref_primary_10_1093_ntr_ntad032
crossref_primary_10_3310_hta23680
crossref_primary_10_3389_fped_2022_896103
crossref_primary_10_1108_JIMA_09_2020_0268
crossref_primary_10_1136_bmjopen_2023_080712
crossref_primary_10_1177_1090198119894589
crossref_primary_10_1097_BPB_0000000000001120
crossref_primary_10_1111_1471_0528_17381
crossref_primary_10_1186_s40814_023_01275_5
crossref_primary_10_1016_j_invent_2017_06_003
crossref_primary_10_1186_s12911_023_02300_6
crossref_primary_10_2196_52841
crossref_primary_10_3389_fpsyg_2024_1438896
crossref_primary_10_1371_journal_pmed_1003779
crossref_primary_10_1016_j_ccrj_2023_04_007
crossref_primary_10_1186_s40814_018_0281_9
crossref_primary_10_3389_fpubh_2024_1304861
crossref_primary_10_1111_codi_15603
crossref_primary_10_1186_s40814_021_00777_4
crossref_primary_10_1352_1944_7558_129_6_476
crossref_primary_10_1186_s40814_018_0303_7
crossref_primary_10_1017_S1041610216001186
crossref_primary_10_1016_j_schres_2019_10_026
crossref_primary_10_1371_journal_pone_0282066
crossref_primary_10_1136_bmjopen_2022_069971
crossref_primary_10_1080_17453674_2020_1755932
crossref_primary_10_1044_2022_AJSLP_22_00180
crossref_primary_10_1136_bmjopen_2023_076304
crossref_primary_10_1186_s40814_017_0138_7
crossref_primary_10_2196_48208
crossref_primary_10_1186_s40814_024_01460_0
crossref_primary_10_1016_j_crad_2019_11_010
crossref_primary_10_1186_s40814_021_00766_7
crossref_primary_10_1186_s40814_023_01274_6
crossref_primary_10_2147_JPR_S400682
crossref_primary_10_1186_s40814_023_01396_x
crossref_primary_10_1080_26408066_2023_2257174
crossref_primary_10_1186_s40814_024_01505_4
crossref_primary_10_3758_s13428_022_02012_1
crossref_primary_10_1002_ejp_1762
crossref_primary_10_1186_s13063_020_04777_2
crossref_primary_10_1186_s13063_024_08661_1
crossref_primary_10_3390_md20070441
crossref_primary_10_3310_phr09050
crossref_primary_10_1136_bmjopen_2016_014422
crossref_primary_10_1016_j_fertnstert_2024_01_040
crossref_primary_10_1177_2050312120927636
crossref_primary_10_1038_s41598_024_65244_5
crossref_primary_10_1016_j_cct_2024_107710
crossref_primary_10_1016_j_jpsychires_2024_04_031
crossref_primary_10_1186_s40814_019_0511_9
crossref_primary_10_2196_44907
crossref_primary_10_1016_j_phanu_2024_100409
crossref_primary_10_1136_bmj_2022_072807
crossref_primary_10_1186_s13063_018_2607_6
crossref_primary_10_1186_s40814_020_00603_3
crossref_primary_10_1016_j_ejpn_2024_06_009
crossref_primary_10_1136_bmjopen_2018_021631
crossref_primary_10_7861_fhj_2022_0101
crossref_primary_10_13181_mji_oa_226115
crossref_primary_10_1093_ageing_afab059
crossref_primary_10_15280_jlm_2022_12_3_105
crossref_primary_10_3310_hta23650
crossref_primary_10_3310_nihropenres_13438_2
crossref_primary_10_3310_nihropenres_13438_1
crossref_primary_10_1136_bmjopen_2019_032924
crossref_primary_10_1111_jocn_16175
crossref_primary_10_1186_s40814_016_0068_9
crossref_primary_10_1136_bmjopen_2023_079404
crossref_primary_10_1177_19322968241310861
crossref_primary_10_1186_s40814_020_00724_9
crossref_primary_10_1002_jclp_22820
crossref_primary_10_1136_bmjopen_2018_021502
crossref_primary_10_1016_j_annemergmed_2017_01_034
crossref_primary_10_1186_s13063_016_1320_6
crossref_primary_10_1186_s40814_019_0500_z
crossref_primary_10_1136_bmjopen_2022_061827
crossref_primary_10_1186_2055_5784_1_1
crossref_primary_10_1177_1087054720959698
crossref_primary_10_1097_PR9_0000000000000924
crossref_primary_10_3390_ijerph181910344
crossref_primary_10_1080_10503307_2023_2169083
crossref_primary_10_1136_bmjopen_2023_076101
crossref_primary_10_1093_jpepsy_jsac075
crossref_primary_10_1007_s43678_023_00586_z
crossref_primary_10_1186_s40814_023_01264_8
crossref_primary_10_1007_s40609_018_0122_z
crossref_primary_10_1177_02692155231202855
crossref_primary_10_1186_s40814_017_0211_2
crossref_primary_10_1016_j_arrct_2021_100160
crossref_primary_10_1136_bmjopen_2020_040636
crossref_primary_10_1186_s40814_018_0312_6
crossref_primary_10_1186_s12884_017_1605_0
crossref_primary_10_1186_s13063_023_07484_w
crossref_primary_10_2196_36275
crossref_primary_10_1161_HYPERTENSIONAHA_118_10911
crossref_primary_10_1136_bmjopen_2020_047277
crossref_primary_10_1016_j_anai_2016_11_012
crossref_primary_10_1016_j_ejon_2020_101866
crossref_primary_10_1136_bmjopen_2021_055071
crossref_primary_10_1061_AJRUA6_RUENG_771
crossref_primary_10_3310_hsdr04240
crossref_primary_10_2196_28667
crossref_primary_10_3310_phr08040
Cites_doi 10.1186/1745-6215-7-9
10.1136/bmj.f1135
10.1016/S0895-4356(03)00141-0
10.1002/sim.2673
10.1002/pst.175
10.1111/j.1467-985X.2006.00408.x
10.1186/1471-2288-10-1
10.1002/sim.4780090113
10.1186/1745-6215-14-166
10.1097/CCM.0b013e3181920e33
10.1081/BIP-200062852
10.1186/1471-2288-14-41
10.1002/sim.4780132309
10.1002/pst.1564
10.2307/3002019
10.1002/bimj.4710380806
10.1136/bmj.b3985
10.1002/pst.185
10.1016/j.jclinepi.2011.07.011
10.1002/pst.139
10.1136/bmj.b1732
10.1002/sim.4780141709
10.1016/j.jspi.2007.05.041
ContentType Journal Article
Copyright COPYRIGHT 2014 BioMed Central Ltd.
Copyright © 2014 Teare et al.; licensee BioMed Central Ltd. 2014 Teare et al.; licensee BioMed Central Ltd.
Copyright_xml – notice: COPYRIGHT 2014 BioMed Central Ltd.
– notice: Copyright © 2014 Teare et al.; licensee BioMed Central Ltd. 2014 Teare et al.; licensee BioMed Central Ltd.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.1186/1745-6215-15-264
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE



MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1745-6215
EndPage 264
ExternalDocumentID PMC4227298
oai_biomedcentral_com_1745_6215_15_264
A540685475
24993581
10_1186_1745_6215_15_264
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations United Kingdom
GeographicLocations_xml – name: United Kingdom
GrantInformation_xml – fundername: Department of Health
  grantid: DRF-2012-05-182
GroupedDBID ---
0R~
123
2-G
29Q
2WC
4.4
53G
5VS
6PF
7RV
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAWTL
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACUHS
ADBBV
ADRAZ
ADUKV
AEGXH
AENEX
AFKRA
AFPKN
AHBYD
AHSBF
AHYZX
AIAGR
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EBD
EBLON
EBS
EJD
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
H13
HMCUK
HYE
IAO
IHR
INH
INR
ITC
KQ8
M1P
M48
M~E
NAPCQ
O5R
O5S
OVT
PGMZT
PHGZM
PHGZT
PIMPY
PSQYO
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
SV3
TR2
TUS
U2A
UKHRP
WOQ
WOW
~8M
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
PMFND
7X8
-5E
-5G
-A0
-BR
ABVAZ
ACRMQ
ADINQ
AFGXO
AFNRJ
C24
5PM
ID FETCH-LOGICAL-b523t-faaa2e4a19677d659142196b8282a23e30c86dbe1798f6b343b7336e8fdef9883
IEDL.DBID RBZ
ISSN 1745-6215
IngestDate Thu Aug 21 18:10:08 EDT 2025
Wed May 22 07:12:26 EDT 2024
Fri Jul 11 03:56:20 EDT 2025
Tue Jun 17 22:05:50 EDT 2025
Tue Jun 10 21:11:40 EDT 2025
Mon Jul 21 06:05:55 EDT 2025
Tue Jul 01 04:00:49 EDT 2025
Thu Apr 24 22:53:14 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-b523t-faaa2e4a19677d659142196b8282a23e30c86dbe1798f6b343b7336e8fdef9883
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink http://dx.doi.org/10.1186/1745-6215-15-264
PMID 24993581
PQID 1548640835
PQPubID 23479
PageCount 1
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_4227298
biomedcentral_primary_oai_biomedcentral_com_1745_6215_15_264
proquest_miscellaneous_1548640835
gale_infotracmisc_A540685475
gale_infotracacademiconefile_A540685475
pubmed_primary_24993581
crossref_primary_10_1186_1745_6215_15_264
crossref_citationtrail_10_1186_1745_6215_15_264
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2014-7-3
2014-Jul-03
20140703
2014-Jul-3
PublicationDateYYYYMMDD 2014-07-03
PublicationDate_xml – month: 07
  year: 2014
  text: 2014-7-3
  day: 03
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Trials
PublicationTitleAlternate Trials
PublicationYear 2014
Publisher BioMed Central Ltd
BioMed Central
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
References J Wittes (2155_CR13) 1990; 9
StataCorp (2155_CR28) 2011
BG Sully (2155_CR6) 2013; 14
A Burton (2155_CR32) 2006; 30
RC Team (2155_CR29) 2013
T Clark (2155_CR4) 2013; 346
SK Sahu (2155_CR21) 2006; 169
BR Kirkwood (2155_CR24) 2003
AJ Vickers (2155_CR2) 2003; 56
2155_CR1
JM Bland (2155_CR20) 2009; 339
P Charles (2155_CR3) 2009; 338
SA Julious (2155_CR17) 2004; 3
RH Browne (2155_CR15) 1995; 14
2155_CR7
FE Satterthwaite (2155_CR26) 1946; 2
J Sim (2155_CR18) 2012; 65
BL Welch (2155_CR27) 1947; 34
M Kieser (2155_CR19) 1996; 38
J Cohen (2155_CR30) 1988
MJ Campbell (2155_CR25) 2007
A Agresti (2155_CR31) 1998; 52
SA Julious (2155_CR16) 2005; 4
T Friede (2155_CR14) 2013; 12
MA Proschan (2155_CR11) 2005; 15
A O’Hagan (2155_CR22) 2005; 4
P Brutti (2155_CR23) 2008; 138
L Thabane (2155_CR9) 2010; 10
MA Birkett (2155_CR12) 1994; 13
AM McDonald (2155_CR5) 2006; 7
EC Lee (2155_CR10) 2014; 14
DM Arnold (2155_CR8) 2009; 37
References_xml – volume: 7
  start-page: 9
  issue: 1
  year: 2006
  ident: 2155_CR5
  publication-title: Trials
  doi: 10.1186/1745-6215-7-9
– volume: 52
  start-page: 119
  issue: 2
  year: 1998
  ident: 2155_CR31
  publication-title: Am Statistician
– ident: 2155_CR1
– ident: 2155_CR7
– volume-title: Statistical Software: Release 12
  year: 2011
  ident: 2155_CR28
– volume: 346
  start-page: f1135
  year: 2013
  ident: 2155_CR4
  publication-title: BMJ
  doi: 10.1136/bmj.f1135
– volume: 56
  start-page: 717
  issue: 8
  year: 2003
  ident: 2155_CR2
  publication-title: J Clin Epidemiol
  doi: 10.1016/S0895-4356(03)00141-0
– volume: 30
  start-page: 4279
  issue: 25
  year: 2006
  ident: 2155_CR32
  publication-title: Stat Med
  doi: 10.1002/sim.2673
– volume: 4
  start-page: 187
  issue: 3
  year: 2005
  ident: 2155_CR22
  publication-title: Pharm Stat
  doi: 10.1002/pst.175
– volume: 169
  start-page: 235
  year: 2006
  ident: 2155_CR21
  publication-title: J R Stat Soc Ser A – Stat Soc
  doi: 10.1111/j.1467-985X.2006.00408.x
– volume: 10
  start-page: 1
  issue: 1
  year: 2010
  ident: 2155_CR9
  publication-title: BMC Med Res Methodol
  doi: 10.1186/1471-2288-10-1
– volume: 9
  start-page: 65
  issue: 1–2
  year: 1990
  ident: 2155_CR13
  publication-title: Stat Med
  doi: 10.1002/sim.4780090113
– volume: 14
  start-page: 166
  issue: 1
  year: 2013
  ident: 2155_CR6
  publication-title: Trials
  doi: 10.1186/1745-6215-14-166
– volume: 37
  start-page: S69
  issue: 1
  year: 2009
  ident: 2155_CR8
  publication-title: Crit Care Med
  doi: 10.1097/CCM.0b013e3181920e33
– volume: 15
  start-page: 559
  issue: 4
  year: 2005
  ident: 2155_CR11
  publication-title: J Biopharm Stat
  doi: 10.1081/BIP-200062852
– volume: 14
  start-page: 41
  year: 2014
  ident: 2155_CR10
  publication-title: BMC Med Res Methodol
  doi: 10.1186/1471-2288-14-41
– volume-title: R: A Language and Environment for Statistical Computing
  year: 2013
  ident: 2155_CR29
– volume-title: Medical Statistics: A Textbook for the Health Sciences
  year: 2007
  ident: 2155_CR25
– volume: 34
  start-page: 28
  year: 1947
  ident: 2155_CR27
  publication-title: Biometrika
– volume: 13
  start-page: 2455
  issue: 23–24
  year: 1994
  ident: 2155_CR12
  publication-title: Stat Med
  doi: 10.1002/sim.4780132309
– volume: 12
  start-page: 141
  issue: 3
  year: 2013
  ident: 2155_CR14
  publication-title: Pharm Stat
  doi: 10.1002/pst.1564
– volume: 2
  start-page: 110
  year: 1946
  ident: 2155_CR26
  publication-title: Biometrics Bull
  doi: 10.2307/3002019
– volume: 38
  start-page: 941
  issue: 8
  year: 1996
  ident: 2155_CR19
  publication-title: Biom J
  doi: 10.1002/bimj.4710380806
– volume: 339
  start-page: b3985
  year: 2009
  ident: 2155_CR20
  publication-title: BMJ
  doi: 10.1136/bmj.b3985
– volume-title: Essential Medical Statistics
  year: 2003
  ident: 2155_CR24
– volume-title: Statistical Power Analysis for the Behavioural Sciences
  year: 1988
  ident: 2155_CR30
– volume: 4
  start-page: 287
  issue: 4
  year: 2005
  ident: 2155_CR16
  publication-title: Pharm Stat
  doi: 10.1002/pst.185
– volume: 65
  start-page: 301
  issue: 3
  year: 2012
  ident: 2155_CR18
  publication-title: J Clin Epidemiol
  doi: 10.1016/j.jclinepi.2011.07.011
– volume: 3
  start-page: 261
  issue: 4
  year: 2004
  ident: 2155_CR17
  publication-title: Pharm Stat
  doi: 10.1002/pst.139
– volume: 338
  start-page: b1732
  year: 2009
  ident: 2155_CR3
  publication-title: BMJ
  doi: 10.1136/bmj.b1732
– volume: 14
  start-page: 1933
  issue: 17
  year: 1995
  ident: 2155_CR15
  publication-title: Stat Med
  doi: 10.1002/sim.4780141709
– volume: 138
  start-page: 1577
  issue: 6
  year: 2008
  ident: 2155_CR23
  publication-title: J Stat Plann Inference
  doi: 10.1016/j.jspi.2007.05.041
SSID ssj0043934
Score 2.5516002
Snippet External pilot or feasibility studies can be used to estimate key unknown parameters to inform the design of the definitive randomised controlled trial (RCT)....
Background External pilot or feasibility studies can be used to estimate key unknown parameters to inform the design of the definitive randomised controlled...
BACKGROUND: External pilot or feasibility studies can be used to estimate key unknown parameters to inform the design of the definitive randomised controlled...
SourceID pubmedcentral
biomedcentral
proquest
gale
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 264
SubjectTerms Computer Simulation
Data Interpretation, Statistical
Feasibility Studies
Humans
Models, Statistical
Pilot Projects
Randomized Controlled Trials as Topic - methods
Randomized Controlled Trials as Topic - statistics & numerical data
Sample Size
SummonAdditionalLinks – databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Ra9swED7aDEZfxrpuq7tsqFAoe_C62LKslI5SxkoptC9toG9CsmUacOwudqHby_767hQ7rUo2yENAsuzo7nLfWXffAewJgzieSpSNSfOQJ5kOzYgquYyQBfoUInihbItLcTbh5zfJzWN5dLeBzcrQjvpJTebll4efv47R4L85g5fiAEF1Egr0XeHIZWytwwv0SymZ6QVfnimg512cMfez-0PLFSs8q34vPaf1_K_7ie_y8yqfOKrT1_CqQ5jsZKESm7Bmqzfw8qI7Q9-CP1eaGIFZM_1t2dxSJrB7RdiwtmbEuYEY1jK0bZa77A5G7OAzypppGBWjsJ44mt1Ny7pl6OzyGrXF5qzLey_xq-sG0hwyjfeZdS3CmOOyfQuT0x_X38_Crg1DaDBKbcNCax1ZrtFW0zQXyXjEUbrCYKwW6Si28ddMitxYoj4rhIl5bIhj0coit8VYyvgdDKq6stvAkiSjI2hJ1bCEHIwc43K4VoywKsrjAI68fVd3C8oNRSTY_gjaoyKxKRKbwg-KLYCDXkwq6yjOqdNGqVyoI8WKKz4vr-jv9e-5-yR5RbqIq2a6K2DAn0YcWuoEwa-QCU-TAIbeTJRB5g3v9rqjaIjS3Cpb3zeK4kfBCRUH8H6hS8vHwjjZkdUFkHpa5u2RP1JNbx1hOI8ijKHkzv8f6wNsIBrkLhc5HsKgnd_bj4i4WvPJGdJfXoMnJw
  priority: 102
  providerName: Scholars Portal
Title Sample size requirements to estimate key design parameters from external pilot randomised controlled trials: a simulation study
URI https://www.ncbi.nlm.nih.gov/pubmed/24993581
https://www.proquest.com/docview/1548640835
http://dx.doi.org/10.1186/1745-6215-15-264
https://pubmed.ncbi.nlm.nih.gov/PMC4227298
Volume 15
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3fS9xAEB7qCeJLsa0_Uq_HFoTiQ9BLNps96ctZFDlQpFY4fFl2kw0enImY-OKL_7oze4l1D_tUOHIHu9lcdnYy32RmvgXYEwZxPJUoG5PmIU8yHZohVXIZIQu0KUTwQtkWF-Lsmk-myfQvTc5SBH8oxQFC5iQUaJnCocvHWoHViKMdJM_8-KZ76qJdXUSQu95dSPKdEZZq2-eeSVp-ML-xTH7W5BszdLoBH1v8yMYLgX-CD7b8DGvnbYT8CzxfaeL7ZfXsybIHS3m-7gVgzZqKEaMGIlTLUHNZ7nI3GHF_31FOTM2o1IR1tNDsfjavGoamLK9wLdictVntc_zp9vqoj5jG69y1G4Axx1S7CdenJ39-nYXtJguhQR-0CQutdWS5Rk1M01wkoyFH2QmDnliko9jGh5kUubFEbFYIE_PYEIOilUVui5GU8Rb0yqq0O8CSJKMAs6RaV8IFRo5wOBwrRtAU5XEAP715V_cLQg1FFNd-C2qbIrEpEpvCD4otgINOTCprCcxpH425co6MFO-csf96Rnetf_f9QZJXpNc4aqbb8gS8NWLIUmOEtkImPE0C6Hs9UQaZ1_y9WzuKmiiJrbTVY63IOxScMG8A24u19Pq30At2VHQBpN4q8-bIbylnt44OnEcRekjy6__N7i6sIxbkLhM57kOveXi03xBvNWYAK-k0HcDqeDy5muD38cnF5e-Be3uBx3MuB04VXwAW4Cvn
linkProvider BioMedCentral
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB5BkYALojxK6AMjISEOod3EdrwVl7aiWvo6QCtVXCw7cdSV0qRq0guX_nVmnKRaV-WElEMkO07WM_bMrL_5BuCTtOjHU4qytVkRc5Gb2E4ok8tKVaJNIYIXQlucyNkZPzgX5wu5ML5WRft1Mfe88hv2iBPrl7mSm-hKi1iixYonHqf1GJ5kQmRUxeDn7u9xN0Z7258sj73Ho8oHRriX814Fpur-hr1gsUI05YJ52n8JLwa_ku30378Mj1z9Cp4eDyfnr-H2lyEeYNbO_zh27Qj_6_8YbFnXMGLaQM_VMVzRrPCYDkac4JeElWkZpaCwkS6aXc2rpmNo4ooGdcQVbEC7V3jbz-s2M_iey6EwGPMMtm_gbP_76d4sHoovxBZj0y4ujTGJ4wZXaJYVUkwnHGUqLUZoiUlSl27lShbWEeFZKW3KU0vMik6VhSunSqVvYaluavcOmBA5HTwryoElf8GqKQ6HY6XoTCVFGsG3YN71VU-0oYn6OmxBTdAkNk1i03ih2CLYHMWk84HYnOprVNoHOEo-8MSXuyfGd_2772eSvKb1jqPmZkhbwJ9GzFl6B11eqQTPRARrQU-UQR40fxx1R1MTgdtq19y0mqJGyckXjmCl16W7z8Lo2FPURZAFWhbMUdhSzy88TThPEoyc1Pv_m90P8Gx2enykj36cHK7Cc_QXuUcrp2uw1F3fuHX0yTq74RfdX2wUMtU
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB6VIlVcUMszfYCRkBCHsN3EdryISymsyqtCQKWKi2UnjliRJqsmvfTCX2fGSap1VU5IOUSy42w8M55v1jOfAZ5LizieSpStzYqYi9zEdkqVXFaqEn0KEbxQtsWxPDrhH0_F6RocjrUw_qyK9tVq7XnlF2y8yX9PlkXZ27mSE8TSIpbosuKpT9S6BbczITKyzm9vf47LMTrcfmt57D3uVd4wwrWi9yrwVddX7BWXFaZTrvin-SbcHYAlO-g1YQvWXH0PNr4MW-f34c93Q0TArF1cOnbuKAHY_zPYsq5hRLWB0NUxNGlW-KQORqTgZ5Qs0zKqQWEjXzRbLqqmY-jjigaVxBVsSHev8Laf2NfM4HvOhpPBmKewfQAn8_c_Do_i4fSF2GJw2sWlMSZx3KCJZlkhxWzKUajSYoiWmCR16X6uZGEdMZ6V0qY8tUSt6FRZuHKmVPoQ1uumdo-BCZHTzrOiIlgCDFbNcDgcK0U0lRRpBG-CedfLnmlDE_d12IKqoElsmsSm8UKxRTAZxaTzgdmcDtiotI9wlLzhiZdXT4zv-nffFyR5TQZPSmiGugX8NKLO0geIeaUSPBMR7AY9UQZ50Pxs1B1NTZTdVrvmotUUNkpOYDiCR70uXf0sDI89R10EWaBlwRyFLfXil-cJ50mCoZPa_r_ZfQobX9_N9ecPx5924A7iRe6zldNdWO_OL9weYrLOPvE29xfcTDKg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Sample+size+requirements+to+estimate+key+design+parameters+from+external+pilot+randomised+controlled+trials%3A+a+simulation+study&rft.jtitle=Trials&rft.au=Teare%2C+M+Dawn&rft.au=Dimairo%2C+Munyaradzi&rft.au=Shephard%2C+Neil&rft.au=Hayman%2C+Alex&rft.date=2014-07-03&rft.pub=BioMed+Central+Ltd&rft.issn=1745-6215&rft.eissn=1745-6215&rft.volume=15&rft_id=info:doi/10.1186%2F1745-6215-15-264&rft.externalDocID=A540685475
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1745-6215&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1745-6215&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1745-6215&client=summon